Collaborators on the winning project include Professor
Their 12-month study will investigate the impact of ECP Immunomodulation on extracellular vesicles and their profiles in response to therapy in patients with graft-versus-host disease (GvHD). A major complication affecting between 40-70% of Hematopoietic Stem Cell Transplant (HSCT) patients, severe GvHD carries a high mortality rate.1
Along with the 2019 Investigator Award, Dr. Crossland's team will receive an educational grant of €50,000 to support their research. The winner was first revealed at the THERAKOS ECP Immunomodulation™ symposium at the 45th Annual Meeting of the
On receiving the award, Dr. Crossland said: "We are honoured to receive the Investigator Award and thrilled that it allows us to look at a potential new pathway into how ECP impacts or modulates immune responses in patients."
"As a pioneer in ECP immunomodulation,
Entries were invited from clinicians and scientists working on translational or outcomes-based research, as well as collaborative projects. Submissions were assessed on a range of criteria, specifically scientific merit, originality and feasibility. The 2020 Advancing ECP Immunomodulation Investigator Award will be open for entries in
For important safety information related to the THERAKOS™ CELLEX™ Photopheresis System, please visit https://www.therakos.co.uk/important-safety-information-hp.
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics. Its Specialty Generics and Amitiza reportable segment includes specialty generic drugs, active pharmaceutical ingredients and AMITIZA® (lubiprostone). To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (
1. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation, Blood. 2012
View original content to download multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-announces-2019-investigator-award-for-pioneering-efforts-in-ecp-immunomodulation-300818630.html
EMEA Media Inquiries: James Tate, The Henley Group, +44(0)1491-570-971, email@example.com, US Media Inquiries, Daniel Yunger, Kekst CNC, +1-212-521-4879, firstname.lastname@example.org, Investor Relations, Daniel J. Speciale, CPA, Vice President, Investor Relations and IRO, +1-314-654-3638, email@example.com